Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b placebo-controlled study of elexacaftor + tezacaftor + ivacaftor in children with cystic fibrosis aged 6 to 11 years with F508del/minimal function genotype
2019-003554-86Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in cystic fibrosis (CF) comparing ELX/TEZ/IVA with Placebo (2 arms). Primary endpoint: Absolute change in lung clearance index 2.5 from baseline through Week 24. Started Mar 2020; status: completed.
02
Drugs
elexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2019-003554-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003554-86.